JUVÉDERM VOLUMA XC for temple hollowing is now available nationwide, Allergan Aesthetics reports.
Following its U.S. FDA approval in March 2024, JUVÉDERM VOLUMA XC is the first and only hyaluronic acid (HA) filler approved to treat moderate to severe temple hollowing in adults over 21.
“In the months since approval, our focus has been on developing and implementing a robust training protocol designed to ensure providers are well versed in the science needed to inject the temple area,” says Carrie Strom, President of Allergan Aesthetics and Senior Vice President at AbbVie, in a news release. “We will continue to provide comprehensive training for this treatment area, as we do with all Allergan Aesthetics products. We look forward to seeing the beautiful results our customers will achieve by adding JUVÉDERM VOLUMA XC for temple into their pan-facial approach.”
Treatment of moderate to severe temple hollowing with JUVÉDERM VOLUMA XC is the newest indication for the JUVÉDERM Collection of Fillers, which currently offers six specifically designed formulated, modified HA fillers to address patients’ varying aesthetic goals: JUVÉDERM VOLUMA XC, JUVÉDERM VOLBELLA XC, JUVÉDERM VOLLURE XC, JUVÉDERM Ultra Plus XC, JUVÉDERM Ultra XC, JUVÉDERM VOLUX XC.
Per FDA requirement for this indication, Allergan Aesthetics is providing a product training program for providers, which includes facial anatomy and considerations for patient selection, safe injection in this area, as well as identification and management of potential complications. Successful completion of this training is necessary prior to the administration of JUVÉDERM VOLUMA XC.
PHOTO CAPTION: JUVÉDERM VOLUMA XC for Moderate to Severe Temple Hollowing is Now Available Nationwide. Actual patient treated with 2.9 mL of JUVÉDERM VOLUMA XC in the temples, 2.1 mL of JUVÉDERM VOLUMA XC in the midface, 2.5 mL of JUVÉDERM VOLUMA XC in the chin, 0.7 mL of JUVÉDERM VOLBELLA XC in the infraorbital hollows, and 1.0 mL of JUVÉDERM VOLLURE XC in the moderate to severe facial wrinkles and folds.
